Overview
This book gives a complete description of online hemodiafiltration, in five sections. It is unique in the systematic and complete way in which hemodiafiltration is described. Each chapter is completed by a point-to-point summary of essential information, in a separate text box. Part of the book is dedicated to the theoretical background of convective clearance. In this part, safety issues and quality control is reviewed (especially on the quality of water for dialysis and substitution fluid), as well as equipment (both dialyzers and machines) with which this treatment can be performed. As recently the results of several randomized controlled trials were available, the effect of hemodiafiltration on hard clinical end points (mortality and morbidity) is discussed in detail. This has not been done before, as the most recent book/journal on hemodiafiltration was published in 2011, before the results of the 3 randomized controlled trials were published. Furthermore, the methodological quality of the trials is discussed by an expert, in order to help the readers in their judgment of the trials Part of the book concentrates on the effect of the treatment on several biomarkers and uremic toxins. Several clinically relevant issues is discussed separately, such as the prescription of anticoagulation during the treatment, drug prescription and clearance for patients treated with hemodiafiltration, and hemodynamic stability. Finally, a practical guide on how to perform the treatment is provided. In this unique section, seemingly simple but important details of hemodiafiltration-treatment is discussed, such as the importance of needle size for blood flow rates, the difference between filtration fraction and substitution ratio, the different targets that can be set and how to reach them. As most literature is mainly focused on theoretical issues, this unique feature really will help the field to perform hemodiafiltration, and answer practical questions.
Full Product Details
Author: Menso J. Nubé ,
Muriel P.C. Grooteman ,
Peter J. Blankestijn
Publisher: Springer International Publishing AG
Imprint: Springer International Publishing AG
Edition: Softcover reprint of the original 1st ed. 2016
Weight: 5.504kg
ISBN: 9783319387505
ISBN 10: 3319387502
Pages: 348
Publication Date: 23 August 2016
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Paperback
Publisher's Status: Active
Availability: Manufactured on demand
We will order this item for you from a manufactured on demand supplier.
Reviews
“It is designed to introduce hemodiafiltration to healthcare professionals and those involved in the dialysis industry, and to discuss how current dialysis therapies have not provided improved survival benefits to patients. … It is aimed at healthcare professionals, regulating bodies, the dialysis industry, patients, and the insurance industry. … This book is very important to modern day nephrology. … an excellent introduction to the modality, its potential future use in treating the dialysis population, and potential for improved patient survival.” (Juan-Carlos Aycnena, Doody's Book Reviews, May, 2016)
It is designed to introduce hemodiafiltration to healthcare professionals and those involved in the dialysis industry, and to discuss how current dialysis therapies have not provided improved survival benefits to patients. ... It is aimed at healthcare professionals, regulating bodies, the dialysis industry, patients, and the insurance industry. ... This book is very important to modern day nephrology. ... an excellent introduction to the modality, its potential future use in treating the dialysis population, and potential for improved patient survival. (Juan-Carlos Aycnena, Doody's Book Reviews, May, 2016)
Author Information
Menso J. Nubé is professor at the department of Nephrology at the VU Vrije Universiteit Medical Center (VUmc) in Amsterdam, the Netherlands. He is involved in research on biocompatibility of hemodialysis treatment and hemodiafiltration since 1993, and an expert in cardiovascular disease in patients with kidney disease. Muriel P.C. Grooteman is internist/nephrologist at the department of Nephrology at the VU Vrije Universiteit Medical Center (VUmc) in Amsterdam. She is involved in research on biocompatibility of hemodialysis treatment and hemodiafiltration since 1993, and a specialist in cardiovascular complications of dialysis treatment. Peter J. Blankestijn is internist/nephrologist and associate professor at the department of Nephrology at the University Medical Center Utrecht (UMCU) in Utrecht, the Netherlands. He is an expert in autonomic dysregulation in patients with end stage kidney disease, and involved in research on hemodialysis and hemodiafiltration since the 90s.
